What changed for Crohn's Disease and Colitis
A plain English summary of what recently moved in the public data Voxsanity tracks for Crohn's Disease and Colitis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 419 to 426 (+7)
- Trials on record 2,486 to 2,497 (+11)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Crohn's Disease and Colitis in July 2026. Voxsanity tracks 14 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 173 trials tracked for Crohn's Disease and Colitis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04173273 · results posted 1 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04173273) tested a medicine called etrasimod, given at two different doses (2 mg and 3 mg), compared to a placebo (a dummy treatment with no active ingredient). The trial was conducted across several sub-studies, involving different groups of participants at different stages — an initial treatment period, an extended treatment period, and a longer-term maintenance phase. In total, across all sub-studies and groups, several hundred participants took part. The largest single sub-study (SS1) began with 100 people on placebo,...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04779307 · results posted 30 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04779307) enrolled 121 children and teenagers with ulcerative colitis — a condition causing ongoing inflammation of the large bowel. Participants received the medicine vedolizumab, with the dose adjusted to their body weight: 150 mg for those weighing 10–15 kg (3 participants), 200 mg for those weighing over 15 kg up to 30 kg (27 participants), and 300 mg for those weighing 30 kg or more (91 participants). The trial was measuring how many participants reached "clinical remission" — meaning their bowel symptoms and bowel-li...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03827109 · results posted 13 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 285 participants across five groups: 55 children in a mentoring program, 56 children in an educational activity program, 55 parents linked to the mentoring program, 56 parents linked to the educational activity program, and 63 mentors. The trial was measuring quality of life and everyday functional ability in young people, comparing those who took part in a mentoring program against those who took part in an educational activity program. Quality of life was measured using a tool called the PedsQL — a questionnaire sco...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04987307 · results posted 13 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 221 adults across four groups to test a medicine called efavaleukin alfa for ulcerative colitis, a condition that causes inflammation in the large bowel. Participants were randomly assigned to receive either a dummy treatment (placebo) or one of three doses of efavaleukin alfa — 400, 1,100, or 1,800 micrograms — given every two weeks. The main thing the trial was measuring was the proportion of participants who reached "clinical remission" (meaning their symptoms and bowel inflammation had reduced to a low, defined le...
-
NCT02531126 · results posted 31 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02531126) enrolled 877 people across four groups studying a medicine called ozanimod. The four groups were: a placebo-then-placebo group (184 people), an ozanimod-then-placebo group (196 people), an ozanimod-then-ozanimod group (443 people), and a smaller open-label ozanimod group (54 people) drawn from an earlier related study. The trial was measuring how many participants experienced side effects or unwanted medical events after starting treatment, as well as tracking several markers related to ulcerative colitis symptom...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04090411 · results posted 16 December 2025
According to the results reported on ClinicalTrials.gov, this trial tested a medicine called PF-06480605 in people with ulcerative colitis (a condition causing inflammation in the large bowel). The trial had two stages: an "induction period" of about 14 weeks, where 246 people were randomly assigned to receive either a placebo (a dummy treatment with no active ingredient) or one of three doses of PF-06480605 (50 mg, 150 mg, or 450 mg); and a longer "chronic period," where participants who completed the first stage were reassigned to various dose combinations, with up to 224 people continuing i...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04232553 · results posted 15 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04232553) enrolled a total of 996 participants across multiple groups, all of whom received at least one dose of study drug. The trial was measuring outcomes in people with Crohn's disease who had previously taken part in an earlier study (referred to as the "AMAM" study). Participants were assigned to different groups depending on what treatment they had received previously — either mirikizumab (the drug being studied), a placebo (a dummy treatment with no active ingredient), or ustekinumab (another medicine) — and then c...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05611671 · results posted 15 December 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called MORF-057 in people with ulcerative colitis, a condition that causes inflammation in the large bowel. A total of 280 people took part, split across four groups: one group took MORF-057 at 200 mg twice daily, one took 100 mg twice daily, one took 100 mg once daily in the morning, and one took a placebo (a dummy pill with no active ingredient). The trial's main goal was to measure how many participants reached "clinical remission" — meaning their bowel symptoms and a camera examination of the bowel (en...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05528510 · results posted 9 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 418 people across three groups to study a medicine called guselkumab in people with ulcerative colitis. One group of 139 people received a placebo (a dummy treatment with no active ingredient), while the other two groups of 139 and 140 people each received guselkumab but on different dosing schedules. The trial measured things like whether participants reached "clinical remission" — meaning their symptoms and bowel inflammation had settled to very low levels based on standardised scoring tools — at 12 and 24 weeks. T...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03440372 · results posted 4 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03440372) looked at people with Crohn's disease, a condition causing ongoing inflammation in the digestive tract. A total of 625 participants were enrolled across two treatment groups — 417 in Treatment 1 and 208 in Treatment 2. The trial measured several things at 12 weeks, including symptom scores, bowel movement frequency, abdominal pain, and the appearance of the intestinal lining on camera examination (endoscopy). The reported data shows the following for the primary measure — the proportion of participants whose ove...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03464097 · results posted 9 October 2025
According to the results reported on ClinicalTrials.gov, this trial involved 550 people with Crohn's disease — a condition causing inflammation in the digestive tract. Participants were split into three groups: 188 people who received the study drug ozanimod throughout the trial, 188 who received ozanimod for the first part then switched to a dummy pill (placebo), and 174 who received a placebo the whole time. The trial measured things like disease activity scores, signs of inflammation seen on camera (endoscopy), stomach pain, and bowel habits, mainly at the 52-week (one-year) mark. It is wor...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03467958 · results posted 17 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03467958) involved people with Crohn's disease, a long-term inflammatory bowel condition. The study was made up of several related parts, with participants across different groups ranging from 13 to 329 people per group. The trial measured ozanimod (0.92 mg) against a placebo (an inactive treatment), tracking disease activity using a scoring tool called the Crohn's Disease Activity Index (CDAI) — essentially a questionnaire covering symptoms like bowel frequency, abdominal pain, and general wellbeing, where a higher score...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04607837 · results posted 15 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04607837) enrolled 155 people in the etrasimod group and 79 people in the placebo group, for a total of 234 participants. The trial was studying etrasimod as a treatment for ulcerative colitis (a condition causing inflammation of the large bowel). The main thing the trial was measuring was how many participants reached "clinical remission" at 52 weeks — meaning their bowel habit scores, bleeding scores, and gut lining appearance (as seen on camera) all fell within defined low-activity ranges on a scoring tool called the Mo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05019742 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05019742) enrolled a very small number of participants — just 3 people in total. They were split across three groups: 2 people received a placebo (a dummy treatment with no active ingredient), 0 people received a 50 mg dose of the study drug SPH3127, and 1 person received a 100 mg dose of SPH3127. The trial was measuring whether participants achieved "clinical remission" (meaning their symptoms improved to a defined level) and "endoscopic remission" (meaning that, when examined internally with a camera, signs of disease ha...
-
NCT04964297 · results posted 6 June 2025
According to the results reported on ClinicalTrials.gov, this trial involved a total of three participants, all of whom were in Cohort 1 (the "Predetermined Points Measurement" group). Cohort 2 (the "Continuous Monitoring" group) had no participants start or complete the study. The trial was measuring levels of two gases — methane and hydrogen — in the body, as well as how quickly a medical device called the Perf-Alert™ could detect the presence of these gases. These gases can be produced in the digestive system, and the trial appears to have been exploring how well this device could pick them...
-
NCT03466411 · results posted 7 May 2025
According to the results reported on ClinicalTrials.gov, this trial (known as GALAXI 1, 2, and 3) enrolled a total of 1,409 adults with Crohn's disease across three related sub-studies. Participants were assigned to receive different doses of a medicine called guselkumab (given by drip into a vein and then by injection under the skin), a comparison medicine called ustekinumab, or a placebo (a dummy treatment with no active ingredient). The trial measured disease activity using two main tools: a scoring system based on symptoms called the CDAI (where lower scores mean less disease activity), an...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05470985 · results posted 22 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05470985) enrolled a very small number of children and adolescents with Crohn's disease — just 3 participants in the ozanimod 0.46 mg group and 2 in the ozanimod 0.92 mg group during the main double-blind treatment phase. The trial was measuring disease activity using two tools: the Pediatric Crohn's Disease Activity Index (PCDAI), which is a scoring system based on symptoms, growth, and blood tests, and the Simple Endoscopic Score for Crohn's Disease (SES-CD), which measures inflammation seen during a camera examination o...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02620046 · results posted 3 April 2025
According to the results reported on ClinicalTrials.gov, this trial looked at vedolizumab 108 mg given as a subcutaneous (under-the-skin) injection to people with two types of bowel disease: ulcerative colitis and Crohn's disease. A total of 288 people with ulcerative colitis and 458 people with Crohn's disease started the study. Of those, 125 and 162 respectively completed it, meaning a notable number of participants left the study early. The trial was primarily measuring how often unwanted medical events (called adverse events) occurred during long-term treatment, and also tracked a range of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03591770 · results posted 21 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03591770) looked at how well a shingles (herpes zoster) vaccine triggered an immune response in adults with ulcerative colitis (UC) who were on different types of medication. Participants were divided into four groups based on their treatment: those taking tofacitinib alone (3 people), those on anti-TNF medication alone (8 people), those on anti-TNF medication combined with a thiopurine (0 people enrolled), and those on aminosalicylates or no immune-suppressing therapy (4 people). In total, 15 people started the trial. Onl...
-
NCT05197049 · results posted 21 February 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called guselkumab in people with Crohn's disease, a condition causing ongoing inflammation in the digestive tract. A total of 350 people took part, split into three groups: 118 received a placebo (a dummy treatment with no active ingredient), 117 received guselkumab at one dose combination, and 115 received guselkumab at a second dose combination. The trial measured several things, including whether participants reached "clinical remission" — meaning their disease activity score dropped below a certain lev...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03512327 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 participants who followed an eating plan called the Autoimmune Protocol (AIP) Diet. All 15 completed the study — none dropped out. The trial was looking at whether this diet was associated with changes in disease activity in people with inflammatory bowel conditions, specifically Crohn's disease and ulcerative colitis. Disease activity was measured using standardised scoring tools: the Harvey Bradshaw Index for Crohn's disease (scored 0–16, where lower scores mean less disease activity) and the Mayo score for ulcer...
-
NCT03926130 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,158 participants in total — 212 in the placebo group (a dummy treatment with no active ingredient), 631 receiving mirikizumab, 309 receiving ustekinumab (a different medicine used for comparison), and 6 adolescents receiving mirikizumab. Most participants completed the study: 159 in the placebo group, 561 in the mirikizumab group, 271 in the ustekinumab group, and 4 in the adolescent group. The trial was measuring two main things in adults with Crohn's disease: first, whether participants showed an early symptom res...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03440385 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called ozanimod in people with Crohn's disease, which is a condition causing ongoing inflammation in the digestive tract. A total of 403 people were assigned to receive ozanimod and 203 people received a placebo (an inactive dummy treatment) — giving roughly 606 participants overall. The trial tracked several measures of disease activity, including a detailed scoring system called the CDAI (which combines things like stool frequency, abdominal pain, and general wellbeing into a single number) as well as...
-
NCT02403323 · results posted 2 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02403323) involved people with Crohn's disease — a condition causing ongoing inflammation in the digestive tract. A total of 751 participants took part across two parts of the study. Part 1 was an open-label extension period, meaning all participants received the study drug, etrolizumab, and knew they were receiving it. Part 2 was a safety monitoring period that did not involve the study drug. The trial was measuring how many participants reached certain disease score thresholds at regular intervals, how many showed improv...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04033445 · results posted 18 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04033445) tested a medicine called guselkumab in people with ulcerative colitis — a condition causing ongoing inflammation in the large bowel. The trial ran in three stages: two early "induction" studies (IS-1 and IS-2) where participants received treatment over the first 12 weeks, followed by a longer "maintenance study" (MS) lasting a further 44 weeks. In total, across all stages, more than 1,000 people took part. The trial measured things like how many people saw a meaningful improvement in their symptoms (called a "cli...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03395184 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03395184) enrolled 244 participants with Crohn's disease across three groups during an initial 12-week period: 79 received a placebo (a dummy treatment with no active ingredient), 93 received a medicine called ritlecitinib, and 72 received a medicine called brepocitinib. After that initial phase, participants who wished to continue moved into a longer follow-up period of up to 52 weeks, where they received lower doses of one of the two active medicines. The trial was measuring how well each treatment reduced visible signs...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02118584 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02118584) involved people with ulcerative colitis — a condition causing inflammation of the large bowel. The trial had two parts. In Part 1, an open-label extension period where all participants received the study drug etrolizumab, 1,026 people started (with 747 of those then moving into Part 2). An additional 49 people joined only for Part 2, a safety monitoring period. The trial was measuring things like how many participants reached "remission" (meaning their disease activity scores fell into a low or minimal range), as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05068284 · results posted 3 October 2024
According to the results reported on ClinicalTrials.gov, this trial tested an investigational medicine called ABBV-154 in people with Crohn's disease. The trial involved different groups receiving either a placebo (a dummy treatment with no active ingredient) or ABBV-154 at various doses and delivery methods — some given by drip into a vein (IV) followed by injections under the skin (SC), and at different timing intervals. In total, across all groups and study phases, around 106 people were enrolled. The trial ran in several stages: a 12-week induction phase (initial treatment period), a 12-we...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01171807 · results posted 24 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 33 children and young people in total — 21 received the active treatment (called Dex 21-P, a form of dexamethasone delivered inside red blood cells) and 12 received a placebo (an inactive treatment). The trial was measuring whether participants responded to treatment, defined as their bowel disease either going into remission or showing a marked improvement, alongside being able to stop or reduce their oral steroid tablets. Several secondary measurements were also taken, including blood markers of inflammation and a s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04877990 · results posted 24 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04877990) enrolled people with one of two bowel conditions — Crohn's Disease or Ulcerative Colitis. In the Crohn's Disease group, 26 people started the pre-treatment stage and 24 moved into the treatment stage. In the Ulcerative Colitis group, 41 people started and all 41 moved into the treatment stage. The trial was primarily measuring things related to monitoring participants' wellbeing during treatment, including any unwanted medical events (called adverse events), blood and urine test results, heart tracing (ECG) readi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
See all 173 reported results for Crohn's Disease and Colitis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is currently directed toward Crohn's Disease and Colitis, and the level of that investment has remained broadly steady from year to year. For patients, this suggests that the condition continues to attract serious and sustained attention from publicly funded researchers. A consistent funding pattern often means research...
See the full Crohn's Disease and Colitis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.